Ryan J. Summers

Hematology | Oncology
2220 N Druid Hills Rd NE
Atlanta, GA 30329

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets.

SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 10, 2026

Paired Tumor/Normal Sequencing Identifies a SEPT9::ABL1 Fusion in a Child With T-Cell Lymphoblastic Lymphoma.

Paired Tumor/Normal Sequencing Identifies a SEPT9::ABL1 Fusion in a Child With T-Cell Lymphoblastic Lymphoma.

Journal: Pediatric blood & cancer
Published: June 04, 2025

Moyamoya Syndrome in Patients With Down Syndrome and Acute Lymphoblastic Leukemia.

Moyamoya Syndrome in Patients With Down Syndrome and Acute Lymphoblastic Leukemia.

Journal: Pediatric blood & cancer
Published: May 28, 2025

SNPing away poor outcomes in T-ALL.

SNPing away poor outcomes in T-ALL.

Journal: Blood
Published: August 29, 2024

How I treat ETP-ALL in children.

How I treat ETP-ALL in children.

Journal: Blood
Published: December 18, 2023

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.

Journal: Blood
Published: April 07, 2023

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.

Journal: bioRxiv : the preprint server for biology
Published: March 30, 2023

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.

Journal: Pharmaceutical research
Published: March 15, 2023

High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia/lymphoma.

High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia/lymphoma.

Journal: Pediatric blood & cancer
Published: March 14, 2023

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.

Journal: Scientific reports
Published: February 28, 2023

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.

Journal: Cancers
Published: October 24, 2022

SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.

SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: July 12, 2022
Showing 1-12 of 18

Last Updated: 09/26/2026